We are valuing an early stage antibiotic drug candidate addressing antibiotic-resistant superbugs. We wish to obtain information on the value of other antibiotic drug candidates either:
- Pre money valuations of a start-up company with a pre-clinical antibiotic
- Corporate sale of private companies that have as their lead drug an anti-biotic with positive phase II data e.g. Cubist acquired Calixa Therapeutics in a deal worth US$402.5 million
- Listed companies that have as their lead drug an anti-biotic that has positive phase II data
Please provide information in an Excel table format including company name, URL, description of transaction including company valuation at time of deal, date of the transaction, short description of the drug candidate and the company and include reference data sources.